R&D on product improvement

Our R&D objectives is firstly to improve the current product portfolio. During the 6 last years, e-Proteins has invested in equipments and new technologies for the avidin production in order to reach the >99% of purity and > 99,5% of activity . This R&D program requires number of investigations , few of them improves the products, others generate new approaches for innovative derivatives.

2018-09-18-eproteins-0122

The second objectives of our R&D is to improve the custom derivatives for our customers in order to optimise those derivatives and to produce them on the long term, as long as their R&D program lasts.

Neutralite avidin has an theoretical specific activity > 16,8 u/mg

In 1990 the Neutralite avidin had a specific activity > 11 U/mg because the process was extremely complex to produce the derivative and its specific activity was quite affected by the chemical ingredients !

In 2012, a new R&D program (NLA-A43) was launched by e-Proteins and this program successfully improves the specific activity to > 14 U/mg

In 2017, a new ambitious program (NLA-A62) has been launched in order to reach > 15,5 U/mg .

In 2018 , e-Proteins started a new R&D program on the Neutralite avidin to reach 16,6 U/mg what is the theoretical maximum specific activity for this derivative.

Ce site utilise des cookies tiers destinés aux statistiques de fréquentation. En acceptant vous nous permettez de mieux vous connaitre et améliorer votre expérience sur notre site.

Accepter Décliner En savoir plus